Drug Development Pharma - March 24, 2015
EC Approves Weight-Loss Drug
The European Commission has granted marketing authorization for Novo Nordisk’s Saxenda® (liraglutide 3 mg) for the treatment of obesity. The authorization covers all 28 European Union (EU) member states. Saxenda® is the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity approved in Europe. Saxenda® is prescribed as a supplement to a reduced-calorie diet and increased physical […]
Drug Development Pharma - March 10, 2015
Health Canada OKs Weight Drug
Health Canada has approved the new drug submission for Novo Nordisk’s Saxenda® (liraglutide), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of chronic weight management. Saxenda® is an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in obese adults and overweight adults with at least one […]
Financing - March 9, 2015
Novo’s IT Shares on the Rise
On its first day on the Copenhagen stock market Friday, Novo Nordisk’s newly public IT business got off to a fast start, with shares rising by as much as 44 percent, according to Reuters. Investors quickly bid up shares in NNIT, which had an offering price of 125 Danish kroner, or about $18—a figure analysts […]
Companies - March 6, 2015
Novo Nordisk on ‘100 Best Companies’ List
For the seventh consecutive year, Novo Nordisk has made the FORTUNE magazine “100 Best Companies to Work For” list, this year ranking 66th. The hundreds of companies that apply each year are evaluated on five criteria: credibility, respect, fairness, pride and camaraderie by the creator of the list, Great Place to Work®. “We strive to […]
Pharma Business - March 3, 2015
Novo Nordisk Adjusts IPO Price
Novo Nordisk is adjusting to the indicative offer price range for the initial public offering (IPO) of NNIT A/S on Nasdaq Copenhagen as further described in the offering circular, which was published on Feb. 23, 2015. According to the company, “The adjustment to the initial indicative offer price range reflects higher than expected investor demand for […]
Uncategorized - February 20, 2015
Positive Phase 2 Trial for Oral Insulin
Novo Nordisk has successfully completed the phase 2 trial for OG217SC, an oral formulation of the long-acting GLP-1 analogue semaglutidea, a form of oral insulin, sending its stock shares climbing. Semaglutide appeared to have “a safe and well-tolerated profile,” according to Novo Nordisk. The 26-week trial included tests of dose range, escalation, efficacy and safety of once-daily doses […]
